Source · Select Committees · Science, Innovation and Technology Committee

First Report - The antimicrobial potential of bacteriophages

Science, Innovation and Technology Committee HC 328 Published 3 January 2024

Report Status

Government responded

Conclusions & Recommendations

33 items (23 recs)

Source

View on Parliament website ↗

Government Response

AI assessment · 33 of 33 classified

Accepted 10

Accepted in Part 1

Acknowledged 7

Deferred 9

Rejected 6

Government response

Government's response to the Science, Innovation and Technology Committee's report 'The antimicrobial potential of bacteriophages' · published 1 Mar 2024

Read the government response ↗ Response on the Index

Recommendations & Conclusions

1 item

24 Conclusion Accepted in Part

Good Manufacturing Practice requirements create impasse for UK phage development

Conclusion

One of the major obstacles to phage clinical trials in the UK has been the requirement for GMP phages. However, regulators require that for phages to achieve GMP standards they must themselves have first been subject to clinical trials. This … Read more

Government Response Summary

The government states that MHRA's draft non-binding advisory guidance will define standards for licensed phages and clarifies that phages for named-patient use require GMP standards but not clinical trials or marketing authorization, thus providing clarity on the described conundrum.

Department for Science, Innovation and Technology

View Details →